You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Poly(ADP-ribose) Polymerase Inhibitors

Showing 1 - 25 of 5,352
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Sarcoma,Soft Tissue, Brachytherapy, Poly(ADP-ribose) Polymerase Inhibitors Trial in Guangzhou (Fluzoparib, Radioactive particle

Recruiting
  • Sarcoma,Soft Tissue
  • +2 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
May 30, 2023

Ovarian Cancer, Ovarian Carcinoma, Platinum-resistant Ovarian Cancer Trial (Pamiparib, Surufatinib)

Not yet recruiting
  • Ovarian Cancer
  • +4 more
  • (no location specified)
Aug 8, 2022

Homologous Recombination Deficiency in Chinese Ovarian Cancer

Not yet recruiting
  • Ovarian Cancer
  • +2 more
  • PARP inhibitor
  • Nanjing, Jiangsu, China
    Xiaoxiang Chen, MD,PhD
Sep 4, 2021

HRD and Resistance to PAPPi in EOC Patients

Recruiting
  • Epithelial Ovarian Cancer
  • +6 more
  • Testing of homologous recombination deficiency
  • Beijing, Beijing, China
    Lei Li
Mar 26, 2022

Ovarian Tumors, BRCA1 Protein, BRCA2 Protein Trial in Worldwide (KU-0059436 (AZD2281)(PARP inhibitor))

Active, not recruiting
  • Ovarian Neoplasms
  • +2 more
  • KU-0059436 (AZD2281)(PARP inhibitor)
  • Brussels, Belgium
  • +4 more
Dec 19, 2022

Ovarian Cancer Recurrent Trial in Birmingham (M4344+Niraparib)

Not yet recruiting
  • Ovarian Cancer Recurrent
  • Birmingham, Alabama
    University of Alabama at Birmingham
Jan 5, 2023

Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, High Grade Endometrioid Ovarian Cancer Trial in Guangzhou (Fluzoparib

Not yet recruiting
  • Ovarian Cancer
  • +4 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Cetntre
Sep 25, 2023

NSCLC, EGF-R Positive NSCLC Trial in Wuxi (Parimparib, Chemotherapy drug, Targeted Therapy Agent)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • EGF-R Positive Non-Small Cell Lung Cancer
  • Wuxi, Jiangsu, China
    Affiliated Hospital of Jiangnan University
Jan 30, 2023

Metastatic Breast Cancer Trial in Herlev, Vejle (PARP inhibitor 2X-121)

Active, not recruiting
  • Metastatic Breast Cancer
  • PARP inhibitor 2X-121
  • Herlev, Denmark
  • +1 more
Feb 1, 2023

Acute Myeloid Leukemia Trial in Baltimore (Decitabine, talazoparib)

Active, not recruiting
Has Results
  • Acute Myeloid Leukemia
  • Baltimore, Maryland
    University of Maryland Greenebaum Comprehensive Cancer Center
May 31, 2022

Prostate Cancer Trial in Philadelphia ([18F]FluorThanatrace, Poly(ADP Ribose) Polymerase 1)

Active, not recruiting
  • Prostate Cancer
  • [18F]FluorThanatrace
  • Poly(ADP Ribose) Polymerase 1
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
May 12, 2022

Endometrial Cancer Trial in Canada (Niraparib, TSR-042)

Active, not recruiting
  • Endometrial Cancer
  • Calgary, Alberta, Canada
  • +6 more
Nov 18, 2021

Metastatic Cancer, Unspecified Adult Solid Tumor Trial in Los Angeles (PARP inhibitor BMN-673, temozolomide, irinotecan HCl)

Completed
  • Metastatic Cancer
  • Unspecified Adult Solid Tumor
  • PARP inhibitor BMN-673
  • +4 more
  • Los Angeles, California
    Jonsson Comprehensive Cancer Center
Sep 22, 2022

Recurrent Glioma, Recurrent Glioblastoma, Poly ADP Ribose Polymerase (PARP) Inhibitor Trial in Hong Kong (Talazoparib)

Recruiting
  • Recurrent Glioma
  • +4 more
  • Hong Kong, Hong Kong
    Department of Clinical Oncology
Aug 19, 2021

Ovarian Cancer, Carcinosarcoma Trial (Pamiparib)

Withdrawn
  • Ovarian Cancer
  • Carcinosarcoma
  • (no location specified)
Aug 3, 2021

Solid Tumor, Extensive-stage Small-cell Lung Cancer, Locally Advanced Breast Cancer Trial in Czechia, Poland (RP12146)

Recruiting
  • Solid Tumor
  • +6 more
  • HoĊ™ovice, Czechia
  • +5 more
Jun 8, 2022

Tumors, Breast Tumors Trial in Japan (talazoparib)

Active, not recruiting
Has Results
  • Neoplasms
  • Breast Neoplasms
  • Nagoya, Aichi, Japan
  • +7 more
Dec 20, 2021

Triple Negative Metastatic Breast Cancer, Advanced Ovarian Cancer, Carboplatin Trial in Belgium, Netherlands, United Kingdom

Active, not recruiting
  • Triple Negative Metastatic Breast Cancer
  • +3 more
  • KU-0059436 (AZD2281)(PARP inhibitor)
  • +3 more
  • Brussels, Belgium
  • +3 more
Dec 19, 2022

Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Boston, Houston

Recruiting
  • Recurrent Fallopian Tube Carcinoma
  • +2 more
  • Boston, Massachusetts
  • +1 more
Jan 12, 2023

Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma Trial in Seattle (biological, drug, other)

Recruiting
  • Biochemically Recurrent Prostate Carcinoma
  • Prostate Adenocarcinoma
  • Durvalumab
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 26, 2023

Breast Tumors Trial in Guangzhou (procedure, drug, biological)

Recruiting
  • Breast Neoplasms
  • Surgery for harvesting tumor-draining lymph nodes
  • +6 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Nov 2, 2023

Neoadjuvant Therapy, High Risk Prostate Cancer, Locally Advanced Prostate Cancer Trial in Nanjing (ADT, Abiraterone Acetate,

Recruiting
  • Neoadjuvant Therapy
  • +3 more
  • Nanjing, Jiangsu, China
    Department of Urology, Drum Tower Hospital, Medical School of Na
Aug 12, 2022

Clear Cell Papillary Renal Tumor, Collecting Duct Carcinoma, Hereditary Leiomyomatosis and Renal Cell Carcinoma Trial in Los

Recruiting
  • Clear Cell Papillary Renal Neoplasm
  • +10 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Oct 25, 2021

Ovarian Cancer Trial in Toronto (Cediranib, Olaparib)

Completed
  • Ovarian Cancer
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
May 3, 2022

Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma Trial in Seattle (Olaparib)

Recruiting
  • Castration-Resistant Prostate Carcinoma
  • Prostate Adenocarcinoma
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 23, 2022